Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Culver who wrote (167)	5/8/2001 6:37:55 PM
From: Heat Shock	Read Replies (1) of 236

David, the recent conference call mentioned partnering. CEO Korpolinski said that they are in active discussions with world-class pharmaceutical companies in both North America and Europe. He said he's hoping for a partnership in the next 12 months. Other conference call notes: - Stressgen has interest in and /or product candidates for HIV, CMV, and Herpes Simplex virus. I believe simian studies on HIV are going on at Harvard. - Antibody-producing vaccines against HPV in the news are type specific, whereas HspE7 acts against multiple HPV types. In June in San Diego, information about the genital warts trial will be revealed. If HspE7 works against genital warts it will show that HspE7 works against multiple HPV types. - the RRP trials will be one for children and one for adults. They said it has the potential to be the "first filing". RRP was described as warts of the upper airways. Someone said the first RRP trial could start and be over within this year Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next